Results 71 to 80 of about 25,648 (169)

Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate

Scientific Reports
Venetoclax has been approved recently for treatment of Acute myeloid leukemia (AML). Venetoclax is a BH3-mimetic and induces apoptosis via Bcl-2 inhibition. However, venetoclax’s effect is still restrictive and a novel strategy is needed.
Renshi Kawakatsu, Kenjiro Tadagaki, Kenta Yamasaki, Tatsushi Yoshida   +3 more
doaj   +1 more source

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

Nature Communications, 2019
The BCL-2 mutation G101V reduces venetoclax affinity and confers drug resistance in patients with chronic lymphocytic leukaemia. Here, the authors present crystal structures and biochemical analyses of venetoclax bound to BCL-2 and the G101V mutant ...
Richard W. Birkinshaw, Jia-nan Gong, Cindy S. Luo, Daisy Lio, Christine A. White, Mary Ann Anderson, Piers Blombery, Guillaume Lessene, Ian J. Majewski, Rachel Thijssen, Andrew W. Roberts, David C. S. Huang, Peter M. Colman, Peter E. Czabotar   +13 more
doaj   +1 more source

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report

Reports
Background and Clinical Significance: Tumor lysis syndrome (TLS) is a rare occurrence in patients treated with venetoclax mono- or combination therapy, and clear protocols guiding TLS prophylaxis are lacking.
Reilly Fankhauser, Alan Lu, Adetola Kassim, Eden Biltibo   +3 more
doaj   +1 more source

Na⁺/H⁺ Exchanger 1 Inhibition Overcomes Venetoclax Resistance in Acute Myeloid Leukemia

Cells
Despite advances with novel targeted agents (e.g., BCL-2 or IDH inhibitors) combined with chemotherapy for acute myeloid leukemia (AML), drug resistance persists.
Shin Young Hyun, Eun Jung Na, Yu Ri Kim, Yoo Hong Min, June-Won Cheong   +4 more
doaj   +1 more source

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia

Cancer Medicine
Background ASXL1 is one of the most frequently mutated genes in acute myeloid leukemia (AML) and retains adverse‐risk status in intensively treated cohorts according to 2022 European Leukemia Net (ELN) risk criteria.
Yiming Cai, Jingwen Rui, Zhengwen Ding, Judan Xie, Zhou Jin, Jinyan Xiao, Yang Xu   +6 more
doaj   +1 more source

The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]

, 2019
Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core  

NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia

Journal of Translational Medicine
Background Acute myeloid leukaemia (AML) comprises a group of heterogeneous and aggressive haematological malignancies with unsatisfactory prognoses and limited treatment options.
Ying Lu, Xia Jiang, Youhong Li, Fenglin Li, Mengting Zhao, Ye Lin, Lili Jin, Haihui Zhuang, Shuangyue Li, Peipei Ye, Renzhi Pei, Jie Jin, Lei Jiang   +12 more
doaj   +1 more source

Low molecular weight compounds from mushrooms as potential Bcl-2 inhibitors: docking and virtual screening studies [PDF]

, 2016
Mestrado com dupla diplomação com o Institut Superieur de Biotechnologie de MonastirMushrooms have the ability to promote apoptosis in tumor cell lines, but the mechanism of action is not quite well understood. Inhibition of the interaction between Bcl-2
Khelifa, Sabrine
core  

Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis

Blood Cancer Journal
Venetoclax showed promising activity in a small phase II trial in relapsed/refractory Waldenström macroglobulinemia (WM). To report the clinical activity of venetoclax and prognostic factors associated with outcomes in a larger cohort, we retrospectively
Y. Sawalha, S. Sarosiek, R. L. Welkie, S. Seif, S. Thapa, S. Zanwar, K. Cahill, R. Treitman, H. Shah, S. Arora, G. Pongas, A. Winter, A. Major, P. A. Riedell, M. L. Palomba, P. Kapoor, A. Grajales-Cruz, K. H. Shain, S. K. Thomas, J. J. Castillo   +19 more
doaj   +1 more source

Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway

Cell Death Discovery
Venetoclax, an inhibitor that selectively targets B cell lymphoma-2 (BCL-2) that has been approved for treating adult acute myeloid leukemia (AML) in combination with hypomethylating agents.
Xibao Yu, Yan Wang, Jiaxiong Tan, Yuchen Li, Pengyue Yang, Xuan Liu, Jing Lai, Yue Zhang, Letong Cai, Yinfeng Gu, Ling Xu, Yangqiu Li   +11 more
doaj   +1 more source